GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (STU:354) » Definitions » Price-to-Owner-Earnings

Collegium Pharmaceutical (STU:354) Price-to-Owner-Earnings : 6.88 (As of Jun. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Collegium Pharmaceutical Price-to-Owner-Earnings?

As of today (2024-06-12), Collegium Pharmaceutical's share price is €30.00. Collegium Pharmaceutical's Owner Earnings per Share (TTM) ended in Mar. 2024 was €4.36. It's Price-to-Owner-Earnings for today is 6.88.


The historical rank and industry rank for Collegium Pharmaceutical's Price-to-Owner-Earnings or its related term are showing as below:

STU:354' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.81   Med: 9.33   Max: 942.59
Current: 6.98

During the past 11 years, the highest Price-to-Owner-Earnings of Collegium Pharmaceutical was 942.59. The lowest was 3.81. And the median was 9.33.


STU:354's Price-to-Owner-Earnings is ranked better than
91.1% of 427 companies
in the Drug Manufacturers industry
Industry Median: 25.08 vs STU:354: 6.98

As of today (2024-06-12), Collegium Pharmaceutical's share price is €30.00. Collegium Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €2.23. Therefore, Collegium Pharmaceutical's PE Ratio for today is 13.48.

As of today (2024-06-12), Collegium Pharmaceutical's share price is €30.00. Collegium Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in was €5.18. Therefore, Collegium Pharmaceutical's PE Ratio without NRI for today is 5.79.

During the past 11 years, Collegium Pharmaceutical's highest PE Ratio without NRI was 45.49. The lowest was 4.22. And the median was 6.62.


Collegium Pharmaceutical Price-to-Owner-Earnings Historical Data

The historical data trend for Collegium Pharmaceutical's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Price-to-Owner-Earnings Chart

Collegium Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 920.00 - - 66.25 13.56

Collegium Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.79 9.00 7.05 13.56 8.12

Competitive Comparison of Collegium Pharmaceutical's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Price-to-Owner-Earnings falls into.



Collegium Pharmaceutical Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Collegium Pharmaceutical's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=30.00/4.36
=6.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Collegium Pharmaceutical  (STU:354) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Collegium Pharmaceutical Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical (STU:354) Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Collegium Pharmaceutical (STU:354) Headlines

No Headlines